Previous close | 116.10 |
Open | 87.74 |
Bid | 127.30 |
Ask | 135.20 |
Strike | 290.00 |
Expiry date | 2024-06-21 |
Day's range | 87.13 - 116.10 |
Contract range | N/A |
Volume | |
Open interest | 14 |
On May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 15,202 shares of the company, according to the SEC Filing.
BOSTON, May 22, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.